Status:
NOT_YET_RECRUITING
Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18-99 years
Brief Summary
Systemic Lupus Erythematosus (SLE) is a chronic invalidating chronic condition, with potential articular, cutaneous, renal, and neurologic involvement. Its pathophysiology is complex, and involves gen...
Detailed Description
Systemic Lupus Erythematosus (SLE) is a chronic invalidating chronic condition, with potential articular, cutaneous, renal, and neurologic involvement. Its pathophysiology is complex, and involves gen...
Eligibility Criteria
Inclusion
- Active systemic lupus erythematosus (SLEDAI \> or = 1)
- Written informed consent
Exclusion
- Chronic or acute infection
- Other active auto-immune condition
- Active cancer
- Age below 18
Key Trial Info
Start Date :
July 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 15 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05424627
Start Date
July 15 2022
End Date
January 15 2027
Last Update
June 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Moulinet
Vandœuvre-lès-Nancy, Lorraine, France, 54500